- Home
- CSR vs UPB Comparison
CSR vs UPB Comparison
Compare CSR & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- UPB
- Stock Information
- Founded
- CSR 1970
- UPB 2021
- Country
- CSR United States
- UPB United States
- Employees
- CSR N/A
- UPB N/A
- Industry
- CSR Real Estate Investment Trusts
- UPB
- Sector
- CSR Real Estate
- UPB
- Exchange
- CSR Nasdaq
- UPB NYSE
- Market Cap
- CSR 1.1B
- UPB 1.1B
- IPO Year
- CSR N/A
- UPB 2024
- Fundamental
- Price
- CSR $66.01
- UPB $16.21
- Analyst Decision
- CSR Buy
- UPB Strong Buy
- Analyst Count
- CSR 7
- UPB 4
- Target Price
- CSR $71.50
- UPB $56.50
- AVG Volume (30 Days)
- CSR 146.2K
- UPB 417.6K
- Earning Date
- CSR 10-28-2024
- UPB 02-14-2025
- Dividend Yield
- CSR 4.54%
- UPB N/A
- EPS Growth
- CSR N/A
- UPB N/A
- EPS
- CSR N/A
- UPB N/A
- Revenue
- CSR $258,642,000.00
- UPB $2,207,000.00
- Revenue This Year
- CSR N/A
- UPB N/A
- Revenue Next Year
- CSR $3.55
- UPB N/A
- P/E Ratio
- CSR N/A
- UPB N/A
- Revenue Growth
- CSR N/A
- UPB 82.10
- 52 Week Low
- CSR $20.10
- UPB $14.97
- 52 Week High
- CSR $76.16
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- CSR 31.30
- UPB N/A
- Support Level
- CSR $68.88
- UPB N/A
- Resistance Level
- CSR $69.36
- UPB N/A
- Average True Range (ATR)
- CSR 1.63
- UPB 0.00
- MACD
- CSR -0.60
- UPB 0.00
- Stochastic Oscillator
- CSR 23.31
- UPB 0.00
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and they conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.